<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01411228</url>
  </required_header>
  <id_info>
    <org_study_id>PB-06-006</org_study_id>
    <nct_id>NCT01411228</nct_id>
  </id_info>
  <brief_title>A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease</brief_title>
  <official_title>A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Protalix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Protalix</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A protocol to extend the assessment of the safety and efficacy of taliglucerase alfa in
      pediatric subjects (2 to &lt;18 years old) with symptoms and clinical manifestations of Gaucher
      disease who completed treatment in Protocols PB-06-002 (switchover study from imiglucerase)
      or PB-06-005 (na√Øve treatment with taliglucerase alfa).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>Baseline, months 9, 12 and 24</time_frame>
    <description>Median and interquartile range. Baseline is the value obtained from the parent study: PB-06-005 for 30 and 60 Units/kg arms and PB-06-002 from Switchover arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chitotriosidase</measure>
    <time_frame>Baseline, months 9, 12 and 24</time_frame>
    <description>Chitotriosidase. Baseline is the value obtained from the parent study: PB-06-005 for 30 and 60 Units/kg arms and PB-06-002 from Switchover arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spleen Volume</measure>
    <time_frame>Baseline, months 12 and 24</time_frame>
    <description>Spleen volume measured by MRI (or ultrasound). Baseline is the value obtained from the parent study: PB-06-005 for 30 and 60 Units/kg arms and PB-06-002 from Switchover arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Count</measure>
    <time_frame>Baseline, months 9, 12, 24 and 33-36</time_frame>
    <description>Platelet count. Baseline is the value obtained from the parent study: PB-06-005 for 30 and 60 Units/kg arms and PB-06-002 from Switchover arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver Volume</measure>
    <time_frame>Baseline, months 12 and 24</time_frame>
    <description>Liver volume by MRI or Ultrasound. Baseline is the value obtained from the parent study: PB-06-005 for 30 and 60 Units/kg arms and PB-06-002 from Switchover arm.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Gaucher Disease</condition>
  <arm_group>
    <arm_group_label>60 Units/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>30 Units/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taliglucerase alfa</intervention_name>
    <description>Taliglucerase alfa for infusion every two weeks for 24 months</description>
    <arm_group_label>60 Units/kg</arm_group_label>
    <arm_group_label>30 Units/kg</arm_group_label>
    <other_name>prGCD, plant cell expressed glucocerebrosidase</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Successful completion of Protocol PB-06-002 or PB-06-005

          -  The subject, parent(s) or legal guardian(s) signs an informed consent and/or assent

        Exclusion Criteria:

          -  Currently taking another investigational drug for any condition.

          -  Presence of neurological signs and symptoms characteristic of Gaucher disease with
             complex neuronopathic features other than longstanding oculomotor gaze palsy.

          -  Presence of any medical, emotional, behavioral or psychological condition that in the
             judgment of the Investigator would interfere with the subject's compliance with the
             requirements of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ari Zimran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shaare Zedek Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Privado de Hematologia E Investigacion Clinica (I.P.H.I.C)</name>
      <address>
        <city>Barrio Asuncion</city>
        <country>Paraguay</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morningside Medi-Clinic</name>
      <address>
        <city>Morningside</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>Paraguay</country>
    <country>South Africa</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2011</study_first_submitted>
  <study_first_submitted_qc>August 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2011</study_first_posted>
  <results_first_submitted>November 6, 2015</results_first_submitted>
  <results_first_submitted_qc>December 11, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 18, 2016</results_first_posted>
  <last_update_submitted>June 20, 2016</last_update_submitted>
  <last_update_submitted_qc>June 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gaucher disease</keyword>
  <keyword>pediatrics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gaucher Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>60 Units/kg</title>
          <description>Taliglucerase alfa: Taliglucerase alfa for infusion every two weeks for 24 months</description>
        </group>
        <group group_id="P2">
          <title>30 Units/kg</title>
          <description>Taliglucerase alfa: Taliglucerase alfa for infusion every two weeks for 24 months</description>
        </group>
        <group group_id="P3">
          <title>Switchover</title>
          <description>Taliglucerase alfa: Taliglucerase alfa for infusion every two weeks for 24 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>60 Units/kg</title>
          <description>Taliglucerase alfa: Taliglucerase alfa for infusion every two weeks for 24 months</description>
        </group>
        <group group_id="B2">
          <title>30 Units/kg</title>
          <description>Taliglucerase alfa: Taliglucerase alfa for infusion every two weeks for 24 months</description>
        </group>
        <group group_id="B3">
          <title>Dose Adjusted</title>
          <description>Taliglucerase alfa: Dose increased from 30 Units/kg to 45 or 60 Units/kg</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.6" spread="3.1"/>
                    <measurement group_id="B2" value="8.6" spread="3.8"/>
                    <measurement group_id="B3" value="13.0" spread="4.1"/>
                    <measurement group_id="B4" value="9.4" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serbia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Paraguay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Singapore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hemoglobin</title>
        <description>Median and interquartile range. Baseline is the value obtained from the parent study: PB-06-005 for 30 and 60 Units/kg arms and PB-06-002 from Switchover arm.</description>
        <time_frame>Baseline, months 9, 12 and 24</time_frame>
        <population>Two Switchover Patients completed 18 months treatment due to early closure of the study site and continued in a compassionate use program</population>
        <group_list>
          <group group_id="O1">
            <title>60 Units/kg</title>
            <description>Taliglucerase alfa: Taliglucerase alfa for infusion every two weeks for 24 months</description>
          </group>
          <group group_id="O2">
            <title>30 Units/kg</title>
            <description>Taliglucerase alfa: Taliglucerase alfa for infusion every two weeks for 24 months</description>
          </group>
          <group group_id="O3">
            <title>Switchover</title>
            <description>Taliglucerase alfa: Maintained dose from PB-06-002 study</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin</title>
          <description>Median and interquartile range. Baseline is the value obtained from the parent study: PB-06-005 for 30 and 60 Units/kg arms and PB-06-002 from Switchover arm.</description>
          <population>Two Switchover Patients completed 18 months treatment due to early closure of the study site and continued in a compassionate use program</population>
          <units>g/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" lower_limit="9.1" upper_limit="12.3"/>
                    <measurement group_id="O2" value="11.2" lower_limit="9.1" upper_limit="12.3"/>
                    <measurement group_id="O3" value="13.5" lower_limit="12.9" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" lower_limit="10.5" upper_limit="13.8"/>
                    <measurement group_id="O2" value="12.5" lower_limit="10.1" upper_limit="13.7"/>
                    <measurement group_id="O3" value="13.9" lower_limit="12.5" upper_limit="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" lower_limit="11.2" upper_limit="13.7"/>
                    <measurement group_id="O2" value="12.8" lower_limit="11.2" upper_limit="14.2"/>
                    <measurement group_id="O3" value="13.7" lower_limit="12.0" upper_limit="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" lower_limit="11.0" upper_limit="14.2"/>
                    <measurement group_id="O2" value="13.1" lower_limit="11.5" upper_limit="14.5"/>
                    <measurement group_id="O3" value="14.2" lower_limit="12.1" upper_limit="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chitotriosidase</title>
        <description>Chitotriosidase. Baseline is the value obtained from the parent study: PB-06-005 for 30 and 60 Units/kg arms and PB-06-002 from Switchover arm.</description>
        <time_frame>Baseline, months 9, 12 and 24</time_frame>
        <population>Chitotriosidase was not analyzed for the subjects in the Switchover group</population>
        <group_list>
          <group group_id="O1">
            <title>60 Units/kg</title>
            <description>Taliglucerase alfa: Taliglucerase alfa for infusion every two weeks for 24 months</description>
          </group>
          <group group_id="O2">
            <title>30 Units/kg</title>
            <description>Taliglucerase alfa: Taliglucerase alfa for infusion every two weeks for 24 months</description>
          </group>
          <group group_id="O3">
            <title>Switchover</title>
            <description>Taliglucerase alfa: Maintained dose from PB-06-002 study</description>
          </group>
        </group_list>
        <measure>
          <title>Chitotriosidase</title>
          <description>Chitotriosidase. Baseline is the value obtained from the parent study: PB-06-005 for 30 and 60 Units/kg arms and PB-06-002 from Switchover arm.</description>
          <population>Chitotriosidase was not analyzed for the subjects in the Switchover group</population>
          <units>nmol/mL*h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34968" spread="20928"/>
                    <measurement group_id="O2" value="30783" spread="17771"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17416" spread="16821"/>
                    <measurement group_id="O2" value="13983" spread="10562"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14677" spread="14418"/>
                    <measurement group_id="O2" value="13823" spread="11525"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7449.5" spread="6966.5"/>
                    <measurement group_id="O2" value="10079" spread="9452.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Spleen Volume</title>
        <description>Spleen volume measured by MRI (or ultrasound). Baseline is the value obtained from the parent study: PB-06-005 for 30 and 60 Units/kg arms and PB-06-002 from Switchover arm.</description>
        <time_frame>Baseline, months 12 and 24</time_frame>
        <population>Two Switchover Patients completed 18 months treatment due to early closure of the study site and continued in a compassionate use program</population>
        <group_list>
          <group group_id="O1">
            <title>60 Units/kg</title>
            <description>Taliglucerase alfa: Taliglucerase alfa for infusion every two weeks for 24 months</description>
          </group>
          <group group_id="O2">
            <title>30 Units/kg</title>
            <description>Taliglucerase alfa: Taliglucerase alfa for infusion every two weeks for 24 months</description>
          </group>
          <group group_id="O3">
            <title>Switchover</title>
            <description>Taliglucerase alfa: Maintained dose from PB-06-002 study</description>
          </group>
        </group_list>
        <measure>
          <title>Spleen Volume</title>
          <description>Spleen volume measured by MRI (or ultrasound). Baseline is the value obtained from the parent study: PB-06-005 for 30 and 60 Units/kg arms and PB-06-002 from Switchover arm.</description>
          <population>Two Switchover Patients completed 18 months treatment due to early closure of the study site and continued in a compassionate use program</population>
          <units>Milliliters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1023.1" spread="336.9"/>
                    <measurement group_id="O2" value="1244.7" spread="317.6"/>
                    <measurement group_id="O3" value="313.0" spread="69.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="524.0" spread="125.7"/>
                    <measurement group_id="O2" value="759.0" spread="194.4"/>
                    <measurement group_id="O3" value="274.1" spread="39.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="395.8" spread="76.8"/>
                    <measurement group_id="O2" value="719.0" spread="161.2"/>
                    <measurement group_id="O3" value="249.5" spread="69.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>33-36 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="306.1" spread="55.1"/>
                    <measurement group_id="O2" value="673.2" spread="128.7"/>
                    <measurement group_id="O3" value="185.4" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Count</title>
        <description>Platelet count. Baseline is the value obtained from the parent study: PB-06-005 for 30 and 60 Units/kg arms and PB-06-002 from Switchover arm.</description>
        <time_frame>Baseline, months 9, 12, 24 and 33-36</time_frame>
        <population>Two Switchover Patients completed 18 months treatment due to early closure of the study site and continued in a compassionate use program</population>
        <group_list>
          <group group_id="O1">
            <title>60 Units/kg</title>
            <description>Taliglucerase alfa: Taliglucerase alfa for infusion every two weeks for 24 months</description>
          </group>
          <group group_id="O2">
            <title>30 Units/kg</title>
            <description>Taliglucerase alfa: Taliglucerase alfa for infusion every two weeks for 24 months</description>
          </group>
          <group group_id="O3">
            <title>Switchover</title>
            <description>Taliglucerase alfa: Maintained dose from PB-06-002 study</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Count</title>
          <description>Platelet count. Baseline is the value obtained from the parent study: PB-06-005 for 30 and 60 Units/kg arms and PB-06-002 from Switchover arm.</description>
          <population>Two Switchover Patients completed 18 months treatment due to early closure of the study site and continued in a compassionate use program</population>
          <units>Platelets/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99600" spread="19185"/>
                    <measurement group_id="O2" value="182000" spread="27009"/>
                    <measurement group_id="O3" value="164587" spread="17321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172600" spread="38667"/>
                    <measurement group_id="O2" value="221400" spread="30626"/>
                    <measurement group_id="O3" value="177400" spread="16795"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172200" spread="39932"/>
                    <measurement group_id="O2" value="233800" spread="32759"/>
                    <measurement group_id="O3" value="189000" spread="7733.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192800" spread="26673"/>
                    <measurement group_id="O2" value="207600" spread="18291"/>
                    <measurement group_id="O3" value="234800" spread="14867"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 33-36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="243750" spread="18585"/>
                    <measurement group_id="O2" value="220200" spread="29231"/>
                    <measurement group_id="O3" value="210000" spread="10000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Liver Volume</title>
        <description>Liver volume by MRI or Ultrasound. Baseline is the value obtained from the parent study: PB-06-005 for 30 and 60 Units/kg arms and PB-06-002 from Switchover arm.</description>
        <time_frame>Baseline, months 12 and 24</time_frame>
        <population>Two Switchover Patients completed 18 months treatment due to early closure of the study site and continued in a compassionate use program</population>
        <group_list>
          <group group_id="O1">
            <title>60 Units/kg</title>
            <description>Taliglucerase alfa: Taliglucerase alfa for infusion every two weeks for 24 months</description>
          </group>
          <group group_id="O2">
            <title>30 Units/kg</title>
            <description>Taliglucerase alfa: Taliglucerase alfa for infusion every two weeks for 24 months</description>
          </group>
          <group group_id="O3">
            <title>Switchover</title>
            <description>Taliglucerase alfa: Maintained dose from PB-06-002 study</description>
          </group>
        </group_list>
        <measure>
          <title>Liver Volume</title>
          <description>Liver volume by MRI or Ultrasound. Baseline is the value obtained from the parent study: PB-06-005 for 30 and 60 Units/kg arms and PB-06-002 from Switchover arm.</description>
          <population>Two Switchover Patients completed 18 months treatment due to early closure of the study site and continued in a compassionate use program</population>
          <units>Milliliters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="991.7" spread="134.7"/>
                    <measurement group_id="O2" value="1236.5" spread="210.6"/>
                    <measurement group_id="O3" value="1345.6" spread="193.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="849.1" spread="121.6"/>
                    <measurement group_id="O2" value="1140.6" spread="180.9"/>
                    <measurement group_id="O3" value="1460.7" spread="227.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="865.5" spread="82.4"/>
                    <measurement group_id="O2" value="1254.4" spread="114.9"/>
                    <measurement group_id="O3" value="1480.7" spread="253.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 33-36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="890.6" spread="118.2"/>
                    <measurement group_id="O2" value="1244.8" spread="89.1"/>
                    <measurement group_id="O3" value="1274.2" spread="189.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>60 Units/kg</title>
          <description>Taliglucerase alfa: Taliglucerase alfa for infusion every two weeks for 24 months</description>
        </group>
        <group group_id="E2">
          <title>30 Units/kg</title>
          <description>Taliglucerase alfa: Taliglucerase alfa for infusion every two weeks for 24 months</description>
        </group>
        <group group_id="E3">
          <title>Switchover</title>
          <description>Taliglucerase alfa: Maintained dose from PB-06-002 study</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Dengue Fever</sub_title>
                <description>(Grade 2 Dengue Fever), which required hospitalization, resolved in 5 weeks and was assessed as not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>LYMPHADENOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>EAR PAIN</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>DENGUE FEVER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Glen Park</name_or_title>
      <organization>Target Health Inc.</organization>
      <phone>212-681-2100</phone>
      <email>gpark@targethealth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

